CA2446390A1 - Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation - Google Patents

Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation Download PDF

Info

Publication number
CA2446390A1
CA2446390A1 CA002446390A CA2446390A CA2446390A1 CA 2446390 A1 CA2446390 A1 CA 2446390A1 CA 002446390 A CA002446390 A CA 002446390A CA 2446390 A CA2446390 A CA 2446390A CA 2446390 A1 CA2446390 A1 CA 2446390A1
Authority
CA
Canada
Prior art keywords
ser
asp
epitope
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002446390A
Other languages
English (en)
Other versions
CA2446390C (fr
Inventor
Ruth Laub
Mario Di Giambattista
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DEPARTEMENT CENTRAL DE FRACTIONNEMENT de la CROIX-ROUGE SCRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446390A1 publication Critical patent/CA2446390A1/fr
Application granted granted Critical
Publication of CA2446390C publication Critical patent/CA2446390C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une séquence de polypeptides antigènes (épitopes du factor VIII), des inhibiteurs dirigés contre cette séquence, et des anti-inhibiteurs dirigés contre ces inhibiteurs. L'invention concerne également une composition pharmaceutique et un dispositif de diagnostic comprenant l'une au moins de ces molécules.
CA2446390A 2001-05-09 2002-05-06 Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation Expired - Fee Related CA2446390C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/853,080 2001-05-09
US09/853,080 US20020068303A1 (en) 1994-07-14 2001-05-09 Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
PCT/BE2002/000070 WO2002090542A2 (fr) 2001-05-09 2002-05-06 Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation

Publications (2)

Publication Number Publication Date
CA2446390A1 true CA2446390A1 (fr) 2002-11-14
CA2446390C CA2446390C (fr) 2012-01-17

Family

ID=25314986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2446390A Expired - Fee Related CA2446390C (fr) 2001-05-09 2002-05-06 Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation

Country Status (7)

Country Link
US (2) US20020068303A1 (fr)
EP (1) EP1399556B1 (fr)
JP (1) JP4500494B2 (fr)
AT (1) ATE525470T1 (fr)
CA (1) CA2446390C (fr)
ES (1) ES2372811T3 (fr)
WO (1) WO2002090542A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0308860A (pt) * 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
GB0713187D0 (en) * 2007-07-06 2007-08-15 Cambridge Entpr biomolecule binding ligands
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649132A (en) 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2276091A1 (fr) * 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Medicaments diriges vers la membrane cellulaire
CA2342967A1 (fr) * 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
WO2002060917A2 (fr) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Methode de traitement de l'hemophilie

Also Published As

Publication number Publication date
US20060051367A1 (en) 2006-03-09
JP4500494B2 (ja) 2010-07-14
WO2002090542A3 (fr) 2003-12-24
ES2372811T3 (es) 2012-01-26
US7981865B2 (en) 2011-07-19
US20020068303A1 (en) 2002-06-06
WO2002090542A2 (fr) 2002-11-14
EP1399556B1 (fr) 2011-09-21
ATE525470T1 (de) 2011-10-15
JP2004535393A (ja) 2004-11-25
WO2002090542A8 (fr) 2004-02-12
CA2446390C (fr) 2012-01-17
EP1399556A2 (fr) 2004-03-24

Similar Documents

Publication Publication Date Title
JP2761402B2 (ja) 普遍的なｔ―細胞エピトープ
US5583108A (en) Vasonatrin peptide and analogs thereof
CA2747721C (fr) Inhibiteurs de tfpi et procedes d'utilisation
Narita et al. The amino acid sequence of cardiotoxin from Formosan cobra (Naja naja atra) venom
Rawitch et al. Thyroglobulin structure-function. The amino acid sequence surrounding thyroxine.
Ansari et al. Complete amino acid sequence of a Lolium perenne (perennial rye grass) pollen allergen, Lol p II
Letellier et al. Mechanisms of formation of IgE-binding factors (soluble CD23)—I. Fcϵ R II bearing B cells generate IgE-binding factors of different molecular weights
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
Hashim et al. Experimental allergic encephalomyelitis: structural specificity of determinants for delayed hypersensitivity
JPH01149799A (ja) Ｌｙｓ―Ａｒｇ―Ａｓｐ配列を含むテトラおよびペンタペプチド、およびそれらの医薬物、とくに抗トロンビン剤、としての使用
CY1112839T1 (el) Πεπτιδια χ-κωνοτοξινες που εχουν ενα αμινοτελικο πυρογλουταμικο οξυ
Vogen et al. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation
US3864481A (en) Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
TAKAGI et al. Amino acid sequence of troponin C obtained from ascidian (Halocynthia roretzi) body wall muscle
Gafvelin et al. A proform of secretin with high secretin-like bioactivity
CA2446390A1 (fr) Epitopes antigenes du factor viii, inhibiteurs diriges contre ces epitopes et leur utilisation
Canova-Davis et al. Characterization of chemically synthesized human relaxin by high-performance liquid chromatography
CA2404429A1 (fr) Polypeptide se36 de l'antigene malaria plasmodium, procede de purification dudit polypeptide, vaccin et methode diagnostique utilisant l'antigene ainsi obtenu
WO2002059146A3 (fr) Peptides presentant une affinite pour la proteine virale gp120, et utilisation de ces peptides
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
RU2503684C2 (ru) Иммуномодулирующие олигопептиды
RU2001127439A (ru) Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом
Matsuda et al. AMINO ACID SEQUENCES OF ALL THE TRYPTIC PEPTIDES FROM THE α POLYPEPTIDE CHAIN OF ADULT HEMOGLOBIN OF THE RHESUS MONKEY (Macaca mulatto) Biochemical Studies on Hemoglobins and Myoglobins. II
Jauregui-Adell et al. Complete amino acid sequence of the sarcoplasmic calcium‐binding protein (SCP‐I) from crayfish (Astacus leptodactilus)
Kopecky et al. Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180507